Vitiligo News and Research

RSS

Vitiligo is a pigmentation disorder in which melanocytes (the cells that make pigment) in the skin are destroyed. As a result, white patches appear on the skin in different parts of the body. Similar patches also appear on both the mucous membranes (tissues that line the inside of the mouth and nose) and the retina (inner layer of the eyeball). The hair that grows on areas affected by vitiligo sometimes turns white.

Skin transplant surgery has long-term benefit for restoring pigmentation caused by vitiligo

A Henry Ford Hospital study has shown that skin transplant surgery has long-term benefit for restoring skin pigmentation caused by the skin disease vitiligo.

27 Jul 2017

Cancer treatment may be effective therapy for psoriasis

HDAC inhibitors, already widely used to treat cancer, may be an effective therapy for psoriasis as well, scientists report.

31 May 2017

Researchers show resident T cells in the skin depend on CD103 molecule for their anti-tumor function

The molecule CD103 is key to the long-term residence of T cells in the skin and to their anti-tumor function, report a team of researchers at the Medical University of South Carolina and the Dartmouth-Hitchcock Norris Cotton Cancer Center In the April 14, 2017, Science Immunology.

28 Apr 2017

New treatment option could provide effective therapy for patients with dermatologic conditions

Alopecia areata, atopic dermatitis and vitiligo are highly visible dermatologic conditions that can have a negative effect on patients' quality of life and overall health. An emerging treatment option, however, could provide effective therapy for patients with these conditions.

3 Mar 2017

Study opens way for targeted local treatments for patchy skin disorders

With the aid of thousands of skin biopsies and over a hundred kilograms of skin, researchers at Karolinska Institutet have observed how two subgroups of immune cell behave in healthy skin.

20 Feb 2017

Contact dermatitis or contact eczema?

There is allergic contact dermatitis, which is mediated through an immune mechanism, this means that the person is specifically allergic to what they have come in to contact with their skin. Their body has had to go through a process whereby they have...

21 Dec 2016

JAK inhibitors show promise in restoring hair growth in patients with alopecia areata

Seventy-five percent of patients with moderate to severe alopecia areata--an autoimmune disease that causes patchy, and less frequently, total hair loss--had significant hair regrowth after treatment with ruxolitinib, reported researchers from Columbia University Medical Center. By the end of their treatment, average hair regrowth was 92 percent.

5 Oct 2016

JAK inhibitors may be first effective treatment for people with alopecia areata

Seventy-five percent of patients with moderate to severe alopecia areata—an autoimmune disease that causes patchy, and less frequently, total hair loss—had significant hair regrowth after treatment with ruxolitinib, reported researchers from Columbia University Medical Center. By the end of their treatment, average hair regrowth was 92 percent.

22 Sep 2016

Study provides new insights into development of skin-depigmenting disease vitiligo

Researchers at the University of Bonn and the Ludwig-Maximilians-Universität of Munich have decoded a new mechanism of how the immune system can specifically attack pigmented cells of the skin.

8 Jun 2016

New research on EdnrB, Wnt signaling pathways could lead to therapies for skin pigment disorders

A pair of molecular signals controls skin and hair color in mice and humans — and could be targeted by new drugs to treat skin pigment disorders like vitiligo, according to a report by scientists at NYU Langone Medical Center.

29 Apr 2016

Researchers successfully treat eczema patients using rheumatoid arthritis drug

Researchers at Yale School of Medicine have successfully treated patients with moderate to severe eczema using a rheumatoid arthritis drug recently shown to reverse two other disfiguring skin conditions, vitiligo and alopecia areata. The study is evidence of a potential new era in eczema treatment, they report.

21 Jul 2015

UT Southwestern dermatologist improves technique to treat skin discoloration from vitiligo

A UT Southwestern Medical Center dermatologist has improved a technique to transplant pigment cells that can repair the affected area of skin discoloration from vitiligo.

17 Jul 2015

Avita Medical’s ReCell technology safe, effective for patients suffering with depigmented skin lesions

Avita Medical Ltd., a regenerative medicine company specializing in the treatment of wounds and skin defects, today announced that statistically significant data from a randomized controlled study demonstrated that its single-use autologous cell suspension technology ReCell was safe and effective in skin repigmentation for patients suffering with depigmented skin lesions caused by vitiligo and piebaldism.

8 Jul 2015

Penn study has implications for developing new cell-based treatments for skin disease

As the main component of connective tissue in the body, fibroblasts are the most common type of cell. Taking advantage of that ready availability, scientists from the Perelman School of Medicine at the University of Pennsylvania, the Wistar Institute, Boston University School of Medicine, and New Jersey Institute of Technology have discovered a way to repurpose fibroblasts into functional melanocytes, the body's pigment-producing cells.

16 Dec 2014

PhotoMedex revenues decrease 12% to $50.1 million in first quarter 2014

PhotoMedex, Inc. reports financial results for the three months ended March 31, 2014 and announces LCA-Vision stockholder approval of PhotoMedex's previously announced acquisition of all outstanding shares of LCA-Vision, a leading provider of laser vision correction services under the LasikPlus brand.

12 May 2014

PhotoMedex Q4 2013 revenues up 16% to $63.5 million

PhotoMedex, Inc. today announced financial results for the fourth quarter and full year ended December 31, 2013.

13 Mar 2014

PhotoMedex terminates exclusive distribution agreement between Radiancy and Ya-Man in Japan

PhotoMedex, Inc. announced today the termination of the exclusive distribution agreement between its wholly-owned subsidiary Radiancy, Inc. and Ya-Man Ltd. for the Japanese market due to, among other things, disputed marketing expenses of approximately $1 million and the failure of Ya-Man to meet its minimum purchase obligations under the agreement.

6 Dec 2013

PhotoMedex third quarter 2013 revenues decrease 19% to $45.9 million

PhotoMedex, Inc. today reported financial results for the three and nine months ended September 30, 2013.

6 Nov 2013

PhotoMedex introduces NEOVA's hyper-active moisturizer, DNA Barrier Accelerator

PhotoMedex, the leader in photodamage repair technology, clinical skincare and medical laser products for more than a decade, introduces NEOVA® SmartSkinCare brand's DNA Barrier Accelerator, a hyper-active moisturizer that rehabilitates and fortifies the skin's essential protective barrier. DNA Barrier Accelerator is available for purchase in dermatology offices nationwide and on NEOVA.com.

4 Oct 2013

New proteins help patients to get more accurate diagnosis of MS

A group of proteins identified by researchers at Stockholm's KTH Royal Institute of Technology could play a role in helping multiple sclerosis patients get more accurate diagnostics about the severity and progress of their disease.

14 Aug 2013